Tiffany Eul Davis Inglis - 12 Mar 2026 Form 4 Insider Report for SERA PROGNOSTICS, INC. (SERA)

Reporting relationship: Chief Medical Officer
Issuer ticker: SERA
Reported as of: 12 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 Mar 2026, 18:28:00 UTC
Prior SEC filing: 15 Oct 2025
Next SEC filing: 15 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Benjamin G. Jackson, Attorney-in-fact

Key filing fact

Tiffany Eul Davis Inglis filed Form 4 for SERA PROGNOSTICS, INC. (SERA) on 13 Mar 2026.

Key facts

This page summarizes Tiffany Eul Davis Inglis's Form 4 filing for SERA PROGNOSTICS, INC. (SERA).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 13 Mar 2026, 18:28.

Change

Previous filing in this sequence was filed on 15 Oct 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002091798 Primary reporting owner

Inglis Tiffany Eul Davis

Relationship: Chief Medical Officer
Address: C/O SERA PROGNOSTICS, INC., 2749 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY
Signature: /s/ Benjamin G. Jackson, Attorney-in-fact
Signature date: 13 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SERA transaction

Class A Common Stock

Award

Transaction value
Shares: +17,437
Change %: +23%
Price: $0.000000^*
Shares after: 92,437
Date: 12 Mar 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SERA transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +27,034
Change %
Price: $0.000000^*
Shares after: 27,034
Date: 12 Mar 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 27,034
Exercise price: $1.99
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each share is represented by a restricted stock unit ("RSU"). These RSUs vest over four years as follows: 1/16 of the original grant amount vests in quarterly installments for four years following the vesting commencement date, which is March 10, 2026, subject to the Reporting Person continuing to provide services to the issuer.

Footnote F2

These stock options vest over four years as follows: 1/48 of the original grant amount vests in monthly installments for four years following the vesting commencement date, which is March 10, 2026, subject to the Reporting Person continuing to provide services to the issuer.